BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $41.00 price target on the biotechnology company’s stock. BTIG Research’s target price would suggest a potential upside of 143.47% from the stock’s current price.
Several other equities research analysts also recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a report on Monday, January 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $61.60.
Get Our Latest Analysis on Arcturus Therapeutics
Arcturus Therapeutics Trading Up 2.9 %
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. The business had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period in the previous year, the firm earned ($0.61) EPS. Sell-side analysts forecast that Arcturus Therapeutics will post -2.31 earnings per share for the current year.
Institutional Investors Weigh In On Arcturus Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARCT. nVerses Capital LLC bought a new stake in shares of Arcturus Therapeutics during the 3rd quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Arcturus Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Arcturus Therapeutics during the second quarter worth $142,000. SG Americas Securities LLC bought a new stake in Arcturus Therapeutics during the third quarter worth $191,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Arcturus Therapeutics by 10.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after acquiring an additional 846 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
See Also
- Five stocks we like better than Arcturus Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Steel Stocks Soaring After Tariff Announcements
- How Investors Can Find the Best Cheap Dividend Stocks
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.